
    
      The primary objective of this study was to evaluate the antihypertensive effect of amiloride
      added to triple antihypertensive treatment in patients with resistant hypertension and type 2
      diabetes mellitus in an open-labelled, non- controlled and non-randomized interventional
      study.

      The secondary objectives were to evaluate the additional effects of amiloride on:

        -  Urinary albumin excretion

        -  Blood pressure control, how many patients reached blood pressure control when amiloride
           was added to previous triple antihypertensive treatment.

        -  Plasminogen and plasmin excretion (ENaC activity) in the micro-and macroalbuminuric
           patients in the cohort.

        -  Urokinase plasminogen activator (uPA) activity
    
  